Free shipping on all orders over $ 500

 About 9 results found for searched term "MEK-IN-6" (0.126 seconds)

Cat.No.  Name Target
M1744 ARRY-162 (Binimetinib) MEK
MEK-162; Binimetinib; ARRY-438162
ARRY-162 (MEK-162; Binimetinib) is a selective, potent inhibitor of MEK and cellular pERK with IC50 of 12 nM and 11 nM, respectively.
M42145 MEK-IN-6 hydrate MEK
MEK-IN-6 hydrate is a MEK inhibitor.
M43554 MEK-IN-6 ERK
MEK-IN-6 is a MEK inhibitor.
M1763 Mirdametinib (PD0325901) MEK
Mirdametinib;PD325901
Mirdametinib (PD0325901) is a highly potent and selective MEK inhibitor with an IC50 in C26 cells of 0.33nM.
M10369 RO5126766 (VS-6766) MEK
CH5126766; VS 6766; Avutometinib
RO5126766 (CH5126766, VS 6766) is a first-in-class dual MEK/RAF inhibitor with IC50 values of 8.2 nM, 19 nM, 56 nM and 160 nM for BRAF V600E, BRAF, CRAF and MEK1, respectively.
M14169 GDC-0623 MEK
RG 7421; MEK inhibitor 1
GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of MEK1 (Ki=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC50=42 nM) versus A375 (BRAFV600E, EC50=7 nM).
M14171 Selumetinib sulfate MEK
AZD6244 sulfate; ARRY-142886 sulfate
Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.
M27786 U0126  MEK
U0126 is a potent, non-ATP-competitive, selective inhibitor of MEK1 and MEK2 with IC50s of 72 nM and 58 nM, respectively.In addition, U0126 is an autophagy and mitophagy inhibitor and inhibits LPA-induced entosis.
M30350 E6201 MEK
ER-806201
E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of MEK1 and FLT3. E6201 inhibits MEK1- induced ERK2 phosphorylation with an IC50 value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC50 value of 91 nM, and MKK6-induced p38 MAPK phosphorylation with an IC50 value of 19 nM. Anti-tumor and anti-psoriasis efficacy.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.